Dexmedetomidine,Ketamine,Butorphanol

Verify with FDA CVM →

111 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
111
Total Reports
14
Deaths Reported
1260.0%
Death Rate

Active Ingredients

Dexmedetomidine,Ketamine,Butorphanol

Administration Routes

UnknownParenteralIntramuscularOther

Species Affected

Cat 109
Dog 2

Most Affected Breeds

Domestic Shorthair 72
Domestic Longhair 9
Cat (unknown) 8
Domestic Mediumhair 8
Siamese 5
Dog (unknown) 1
British cat 1
Bengal 1
Rex (unspecified) 1
Scottish Fold Shorthair 1

Most Reported Reactions

Behavioural disorder NOS 21
Hyperactivity 18
Dilated pupils 14
Not eating 12
Dysphoria 12
Elevated temperature 11
Lethargy (see also Central nervous system depression in Neurological) 10
Hiding 9
Not sleeping 9
Application site alopecia 8
Seizure NOS 7
Weight loss 7

Outcome Breakdown

Ongoing
38 (34.2%)
Recovered/Normal
32 (28.8%)
Outcome Unknown
27 (24.3%)
Euthanized
7 (6.3%)
Died
7 (6.3%)

Data Summary

Metric Value
Total adverse event reports 111
Reports involving death 14
Case-fatality rate (reported events) 1260.0%
Distinct species in reports 2
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dexmedetomidine,Ketamine,Butorphanol Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 111 adverse event reports referencing Dexmedetomidine,Ketamine,Butorphanol, including 14 reports in which the animal died — a 1260.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dexmedetomidine,Ketamine,Butorphanol. Reported administration routes include Unknown, Parenteral, Intramuscular, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dexmedetomidine,Ketamine,Butorphanol reports are Cat (109 reports), Dog (2 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (72), Domestic Longhair (9), Cat (unknown) (8) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dexmedetomidine,Ketamine,Butorphanol are Behavioural disorder NOS (21), Hyperactivity (18), Dilated pupils (14), Not eating (12). Of the 111 reports with a coded outcome, Ongoing is the leading category at 34.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dexmedetomidine,Ketamine,Butorphanol.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial